|
1998
|
|
Imminent
Changes for Our Field
This report discusses the most significant issues
concerning the transition in federal oversight from the FDA to CSAT,
using an accreditation model in place of process oriented regulation. |
| |
|
|
|
New
Support for Methadone Maintenance Treatment through a Realistic National
Drug Policy
This report expresses how General McCaffrey
and ONDCP have taken on an important leadership role, which we believe
will lead to a major expansion in methadone treatment throughout the
United States. |
| |
|
|
|
Neurobiology
of Heroin Addiction and of Methadone Treatment
The following article represents the major text
of Dr. Avram Goldstein's plenary speech during the April 1997 National
Conference. It is increasingly important for treatment providers to
understand the neurobiology of addiction in order to effectively use
the pharmacology of methadone and other pharmacotherapies, such as
LAAM and developing treatment agents. |
| |
|
|
|
Policy
For Treating Methadone Maintained Patients in Private Medical Settings
This articles focuses on our Association's criteria
for implementing a policy of referring stabilized methadone maintained
patients from our treatment programs to off site physician based settings,
in advance of the NIH panel recommendations. |
| |
|
|
|
Buprenorphine
and the Use of Clinically Effective Medications in Treating Chronic
Opiate Dependence
This article displays AATOD's support for the
new medications (LAAM and Buprenorphine) that are being made available
to treat chronic opioid dependent individuals as well as some comparisons
between Buprenorphine and methadone. |
| |
|
|
|
Ultra
Rapid Detoxification
Our office has been contacted frequently about
the use and efficacy of Ultra Rapid Opiate Detoxification. AATOD will
not take any official position until we have access to studies regarding
ultra rapid opiate detoxification. Therefore, AATOD has asked agencies
within the federal government to conduct such studies. |
| |
|
|
|
Recommendations
for Hepatitis Prevention and Treatment
Our Association's Policy Committee, Janice Kauffman,
(Chair, Massachusetts), Michael McAllister (NY), Paul McLaughlin(CT),
Dr. J. Thomas Payte (ASAM), Michael Rizzi (RI) and Dr. George Stavros
(AZ), has developed basic recommendations for the prevention and treatment
of Hepatitis C in our patient population. |
|
|
|
|
Reports
from the States
Updates are provided for the states of Arizona,
Connecticut, Massachusetts
and Rhode Island. |
| |
|
|
|
Increasing
Support For Treatment in the Medical Establishment
The
National Institutes of Health (NIH) convened a Consensus Development
Conference on Effective Medical Treatment of Heroin Addiction during
November 1997. The conference was co-sponsored by the National Institute
on Drug Abuse (NIDA) in conjunction with the National Institutes of
Health Office of Medical Applications of Research and the NIH Office
of Research on Women's Health. This conference represented a landmark
opportunity to focus on the efficacy of methadone treatment and to
develop a system, which would overcome the barriers of the past three
decades. This article describes the panel's recommendations in further
detail. |
1999
|
|
News
From the Front
This is an update of the Notice for Proposed
Rule Making (NPRM), which intends to shift federal regulatory oversight
authority for methadone treatment away from the FDA to an accreditation
process, which will be managed by CSAT. In addition, the implications
of the Drug Abuse Treatment Act (S.324) (H.R. 2634) are discussed.
|
| |
|
|
|
Association
Survey Identifies Greater Numbers in Methadone Treatment
We had been receiving conflicting reports concerning
the number of opiate dependent individuals enrolled in methadone maintenance
treatment programs. Consequently, The Association decided it was time
to find out what the treatment system consisted of and, in response
to all the varying reports, we conducted a survey.
The survey requested census and related information from the State
Methadone Authorities and the designated State Methadone Provider
Contact representatives in the forty-two states, (in addition to the
District of Columbia) that provide methadone treatment services. Read
more about the findings of the survey. |
| |
|
|
|
1998
Methadone Maintenance Program and Patient Census in the U.S.
|
| |
|
|
|
Notice
for Proposed Rule Making - Change in Federal Oversight for Methadone
Treatment
This article documents the survey results that
our Associated compiled from methadone treatment programs and State
Methadone Authorities regarding the direct and indirect costs of accreditation
for the Association's testimony on November 1, 1999 when the federal
interagency hearing convened to receive guidance from the field. Also,
this provides an in-depth discussion on the Association's stance on
accreditation and recommendations to the federal government in regulating
the accreditation process.
Narcotic Treatment Programs Best Practice Guidelines
The DEA and our Association is in the final stages of developing the
Best Practice Guidelines. This article explicitly states what
the upcoming Best Practice Guidelines will encompass. |
| |
|
|
|
Narcotic
Treatment Programs Best Practice Guidelines |
| |
|
|
|
Drug
Addiction and Treatment Act (S.324) (H.R.2634)
The importance of the legislation would be to
make new medications, such as Buprenorphine, available to chronic
opiate dependent individuals through physician offices. This would
reverse more than 75 years of having physicians prohibited from treating
such a disease in their individual medical practices. This article
makes reference to some articles regarding the efficacy of buprenorphine
as well our Association's position. |
| |
|
|
|
Association
Expands Its Training Course to Physicians and Clinicians in Methadone
Treatment Programs
The Association's Board of Directors authorized
an expansion of this opportunity so that we could site such training
events in different regions of the United States. This article discusses
the results of the first independent training (Atlanta during September
1999) from our National Methadone Conference. |
| |
|
|
|
Patient
Recognition Ceremony
The Association has been supporting the broad
implementation of patient recognition ceremonies in methadone treatment
program. We recently participated in such an experience in Pawtucket,
Rhode Island when the Addiction Recovery Institute convened its annual
celebration dinner. |
| |
|
|
|
Association
Introduces Management Training Symposia
The Association convened the first management-training
symposium in Washington, D.C. on December 8, 1998 with the assistance
of an educational grant from Glaxo Wellcome, Inc. Read more about
the highlights of this event. |
| |
|
|
|
Expanding
Access to Medical Maintenance Treatment
These
are the criteria for stable patient referral from methadone programs
to office-based medical practice settings. |
2000
|
|
"Methadone
Treatment: Our Vision for the Future"
Remarks by Barry R. McCaffrey
Director, Office of National Drug Control Policy
April 12, 2000
Part I of speech highlights those who have been visionaries in the
methadone field - individuals who informed the discussion on opiate
addiction through trailblazing efforts. Part II examines what we know
about addiction. Part III looks at the status of drug treatment and
what we are doing to make it more available. Part IV provides an update
on our past-year progress in implementing a new system of federal
oversight for treatment programs, particularly methadone. Part V outlines
policy issues that currently define the methadone debate. Finally,
Part VI articulates our vision for the future of methadone treatment.
|
|
 |
